Previous 10 | Next 10 |
home / stock / abscf / abscf news
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT Paris, March 7, 2024, 3pm CET AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Sc...
PRESS RELEASE TWO NEW FINANCIAL ANALYSIS FIRMS INITIATE COVERAGE OF AB SCIENCE Paris, March 6, 2024, 8.15pm CET AB Science SA (Euronext - FR0010557264 - AB) announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated the coverage of th...
PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY MARCH 4, 2024 FROM 6.30PM TO 7.30PM CET Paris, 29 February, 2024, 11.30am CET AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CE...
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS ISSUED A NOTICE OF NON-COMPLIANCE-WITHDRAWAL (NON/w) FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AB SCIENCE INTENDS TO SUBMIT A REQUEST FOR RECONSIDERATION Paris, 26 February, 2024, 6.15pm CET AB Science ...
PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN MEDICINES AGENCY IS EXPECTED DURING THE SECOND QUARTER OF 2024 Paris, 26 Janu...
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2036 IN THE TREATMENT OF MASTOCYTOSIS THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY PROTECTION STRATEGY BASED ON MEDICAL USE PATENTS Pa...
PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN SICKLE CELL DISEASE ON THURSDAY NOVEMBER 30, 2023, FROM 3PM TO 4PM CET Paris, 28 november, 2023, 7.15pm CET AB Science SA (Euronext – FR0010557264 – AB) will host a li...
PRESS RELEASE THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)". THIS PROGRAM WILL FUND A MASITINIB PHASE 2 CLINICAL TRIAL ...
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORM ATION FOR THE FIRST HALF OF 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development strategy based on two platforms: the late-stage masitinib platform and the new microtubule platform Mas...
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE EUROPEAN MEDICINES AGENCY'S TIMETABLE FOR EXAMINATION OF THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOT RO PHIC LATERAL SCLEROSIS BASED ON THE UPDATED TIMETABLE, A...
News, Short Squeeze, Breakout and More Instantly...
Ab Science Paris Ord Company Name:
ABSCF Stock Symbol:
OTCMKTS Market:
PRESS RELEASE AB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19 Paris, 8 July 2024, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announces the results of a Phase 2 study evaluating masitinib in COVID-19. This rando...
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, May 31, 2024, 4.30pm CET AB Science SA (Euronext - FR0010557264...
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 29 May, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the Commit...